7699-22-1

Basic information

• Product Name: 1,3-dihydro-5-Methoxy-1-Methyl-2H-Indol-2-one
• Synonyms: 1,3-dihydro-5-Methoxy-1-Methyl-2H-Indol-2-one
• CAS NO: 7699-22-1
• Molecular Formula: C10H11NO2
• Molecular Weight: 177.203
• Mol File: 7699-22-1.mol
• Article Data: 4

Chemical Properties

• CAS DataBase Reference: 1,3-dihydro-5-Methoxy-1-Methyl-2H-Indol-2-one(CAS DataBase Reference)
• NIST Chemistry Reference: 1,3-dihydro-5-Methoxy-1-Methyl-2H-Indol-2-one(7699-22-1)
• EPA Substance Registry System: 1,3-dihydro-5-Methoxy-1-Methyl-2H-Indol-2-one(7699-22-1)

Safety Data

• Hazardous Substances Data: 7699-22-1(Hazardous Substances Data)

Usage

Type of compound

Chemical compound

Derivative of

Indole (a heterocyclic aromatic organic compound)

Also known as

5-methoxytryptophol

Occurrence

Naturally occurring alkaloid found in various plant species

Psychoactive properties

Potential sedative and hallucinogenic effects

Therapeutic applications

Studied for treating mood disorders and substance abuse

Role in biosynthesis

Involved in the biosynthesis of serotonin, a neurotransmitter regulating mood, appetite, and sleep

Upstream product

• 75-75-2 methanesulfonic acid 
• 148518-74-5 N-methyl-N-(4-methoxyphenyl)-α-carbomethoxy-α-diazoacetamide 
• 7699-18-5 5-methoxyindolin-2-one 
• 77-78-1 dimethyl sulfate 
• 74-88-4 methyl iodide 
• 67-56-1 methanol 
• 148518-76-7 N-benzyl-N-(3,4-dimethoxyphenyl)-α-carbomethoxy-α-diazoacetamide 

Downstream Products

• 110554-80-8 3-(4-diethylamino-phenylimino)-5-methoxy-1-methyl-indolin-2-one 
• 6062-24-4 1-methyl-5-hydroxy-2-indolinone 
• 855600-28-1 1-(5-methoxy-1-methyl-2-oxo-indolin-3-ylidenemethyl)-2-oxo-cyclohexanecarboxylic acid ethyl ester 
• 1443787-61-8 C₂₀H₂₁NO₅ 

Relevant articles and documents

KINASE INHIBITORS AND METHOD OF TREATING CANCER WITH SAME

The invention is directed to a compound represented by the following structural formula and pharmaceutically acceptable salts thereof: Compounds represented by this structural formula are kinase inhibitors and are therefore disclosed herein for the treatment of cancer. Definitions for the variables in the structural formula are provided herein.

Substituted oxindoles

The present invention relates to novel substituted oxindoles of the formula I as defined below and related compounds, pharmaceutical compositions comprising such compounds, and the use of such compounds as inhibitors of phosphodiesterase ("PDE") type IV. The compounds of this invention are useful in the treatment of AIDS, asthma, rheumatoid arthritis, osteoarthritis, bronchitis, chronic obstructive airways disease, psoriasis, allergic rhinitis, atopic, dermatitis, shock, other inflammatory diseases, and other conditions where the action of phosphodiesterase type IV is implicated.